Psychemedics Test for Cotinine (metabolite of Nicotine) Detection Cleared by FDA
A New and Cost-Effective Tool to Detect and Deter Nicotine use
ACTON, MA, April 29, 2020 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ: PMD), the world leader and pioneer in detecting drugs of abuse using hair analysis, today introduced the first FDA-cleared hair test for cotinine, the predominant metabolite for nicotine. This test provides a way for schools and businesses to detect the ingestion of nicotine by all methods including smoking or the use of electronic cigarettes. Hair testing provides several significant advantages over other methods of testing including a 90-day lookback period for the ingestion of drugs.
The popularity of electronic cigarettes has skyrocketed in society and particularly in schools. The following data support the troubling increase educators are seeing in the use of e-cigarettes and vaping.
Results from the 2019 National Youth Tobacco Survey paint a disturbing picture:
- More than 5M youth used e-cigarettes in 2019 (up 38% from 2018)
- 1.6M youth used e-cigarettes on 20 or more days a month
- 27.5% of high school students and 10.5% of middle school students use e-cigarettes
“Many of our school clients have asked us for this test as they see it as a key tool to help them deter their students from the increasing threat posed by vaping. Our new 510(k) approved nicotine assay allows us to offer a nicotine test at an affordable price beneficial to schools,” stated Raymond C. Kubacki, Chairman, and CEO of Psychemedics Corporation.
Psychemedics’ new cotinine test is an accurate and economical way to equip educators and companies alike with the capability to quickly detect people using nicotine. This additional test reinforces the company’s leadership in scientific innovation and underscores the Psychemedics position as the trusted partner to Fortune 500 companies and schools to create drug-free workplaces and campuses.
Psychemedics’ innovation extends a sustained track record of industry firsts
Since pioneering the hair testing industry in 1986, Psychemedics has consistently been first with innovations that advance the science of detecting drugs of abuse using hair, including but not limited to being the:
- First and only company to patent a process that releases virtually 100% of ingested drugs from inside the hair
- First and only company to develop and utilize an FBI-validated extended wash process that eliminates external contamination as a contributor to a positive hair test result
- First company to develop and market hair tests for ecstasy (MDMA), synthetic opioids, Adderall, synthetic cannabinoids, and EtG (alcohol)
- First and only company to have its hair test for benzodiazepines cleared by the FDA
- First and only company to have its hair test for fentanyl cleared by the FDA
Availability of the FDA-cleared test for cotinine
The Psychemedics FDA-cleared hair test screen for cotinine is available on April 29, 2020. Psychemedics clients can add the screen to their drug panels and should contact their account representative for details. Medical Directors, Environmental Health and Safety Professionals, and Educators who wish to learn more about this and other tests can find information at www.psychemedics.com.
About Psychemedics
Psychemedics is the pioneer and global leader of testing for drugs of abuse using hair analysis. With over 30 years of continuous innovation, Psychemedics is the only company to develop and patent a process that releases virtually 100% of ingested drugs from the inside of the hair. We believe Psychemedics’ superior science delivers the most sensitive FDA 510(k) cleared tests in the world resulting in unmatched detection rates.
Psychemedics’ results, science, and people are trusted by the world’s most safety-sensitive industries, the largest law enforcement agencies as well as by schools and elite institutions around the globe. A wide cross-section of companies from a diverse set of industries including many companies in the Fortune 500 rely on Psychemedics to ensure they are building drug-free, safe, and productive workforces. We make businesses, our nation’s highways, and campuses safer.
Psychemedics is the standard against which all others measure themselves for sensitivity, quality, and innovation to stay ahead of the ever-changing illicit drug landscape.
The Psychemedics web site is www.psychemedics.com
Charles Doucot
Executive Vice President
(978) 206-8220
Charlesd@psychemedics.com
Recent Posts
Archives
- January 2021
- August 2020
- May 2020
- April 2020
- March 2020
- September 2019
- April 2019
- March 2019
- June 2018
- May 2018
- February 2018
- January 2018
- September 2017
- August 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- January 2016
- December 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- November 2008
- October 2008
- September 2008
- March 2008
- January 2008
- November 2007